CMND

Clearmind Medicine Inc. Common Shares (CMND) | Rumor.io

Clearmind Medicine Inc. Common Shares

CMND

Attention (50-day avg)0%

Attention rank (50-day avg)#1,351

Bullish sentiment (50-day avg)92%

Price to earnings ratio0.17

Market capitalization2.7M

Earnings per share-57.8

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-3.9M

Social

What share of all stock conversation is about CMND?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Sep 17

Clearmind Medicine Inc. ($CMND) presented its non-hallucinogenic psychedelic research at a historic FDA hearing on the future of psychedelic-based medicine.
Lead candidate MEAI is being studied at Yale and Johns Hopkins for alcohol use disorder, a condition with a Phase 2a trial ongoing.
Clearmind Medicine's stock ($CMND) is experiencing increased volume, with some analysts predicting a potential price range of $1.50-2.

Generated by AI

Sentiment

Of the messages about CMND that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	88.66% -11.34	76.66% -9.51
Bearish	—	—	11.34% +11.34	23.34% +9.51

Bullish· Aug 31

The company's low float and high short interest (CTB) make it a prime target for a squeeze, which could lead to significant price increases.
The stock's current setup, with a coiling pattern, suggests it is preparing for a major pop, potentially exceeding $3 per share.
With a large number of warrants outstanding, the company's stock is expected to see significant buying pressure, making it a good opportunity for investors to make a profit.

Bearish· Sep 4

The company's stock price has been declining, with a 52-week low expected to be reached later in the day.
There is a high level of short selling in the stock, with many investors expecting it to collapse.
The company's stock has been unable to recover from a significant decline, with no interest from buyers and a low price point that may not be able to cross $2.

Generated by AI

Topics

Of the messages about CMND that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	95.83%	83.96%	38.56%
Technical Analysis	100%	4.17%	14.15%	25.18%
Controversies	0%	0%	1.89%	0.06%
Analysts	0%	0%	0%	21.39%
Earnings	0%	0%	0%	0.03%
Macro	0%	0%	0%	14.78%

Announcements· May 29

Clearmind Medicine Inc. ($CMND) filed a Japanese patent application for MEAI, a non-hallucinogenic psychedelic compound for depression treatment.
The patent filing is part of Clearmind's expansion of its global intellectual property portfolio, which spans multiple jurisdictions with multiple granted patents and applications.
Clearmind Medicine's stock surged 95% after the patent filing, with the company also advancing its CMND-100 Phase I/II trial for alcohol use disorder at Johns Hopkins and Yale.

Technical Analysis· Apr 20

The 10M MACD for CMND has crossed, indicating strong buying pressure and a potential move.
The stock has halted after a strong push, suggesting an imbalance between buyers and sellers, with the reaction after the reopen being crucial.
CMND is breaking out on volume, with a tight float and consolidation finally breaking, and the price action speaking for itself.

Generated by AI

Community

Of the messages about CMND, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	74.58%	33.06%
Newcomers	0%	0%	25.42%	66.94%

Regulars· Sep 4

Clearmind Medicine has signed a definitive agreement to acquire a 51% stake in Charging Robotics, a wireless charging company for automated parking and robotaxis, for $2.5 million.
The acquisition is expected to add wireless charging technology to Clearmind Medicine's product portfolio, potentially expanding its reach in the automated parking and robotaxis markets.
Regular participants are divided on the implications of this acquisition, with some viewing it as a positive development and others warning of potential liquidity issues or a "pump and dump" scenario.

Newcomers· Sep 4

Clearmind Medicine Inc. has announced a $2.5M deal to acquire a 51% stake in an EV wireless charging firm, Charging Robotics, and also expects to close a $1.5M loan at 4%.
The acquisition and news release have caused a strong reaction on the market, with some users speculating about the potential impact on the company's stock price.
Some users are skeptical about the news and the potential for a short attack, with one user stating that there is no reason for trading view to put this news out there if it's not true.

Generated by AI

The U.S. Patent Applications Cover Proprietary Combinations of NeuroThera's PEA Technology With LSD, Ketamine and Ibogaine for Potential Therapeutic Applications, Including Mental Health Disorders, Such as Depression and PTSD as Well as Substance Use...

6d agoYahoo Finance

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developi

6d agoYahoo Finance

Clearmind testifies at FDA hearing on psychedelic therapies

12d agoInvesting.com

Clearmind enrolls first AUD patients in CMND-100 clinical trial

19d agoInvesting.com

Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million

25d agoYahoo Finance

Clearmind Medicine Stock Slides Friday: What's Happening?

25d agoBenzinga

Also Discussed

Investors talking about CMND also mention

#	Name	Attention
1	SciSparc Ltd.SPRC	0%+0
2	Psyence Biomedical Ltd.PBM	0%new
3	UTime LimitedWTO	0%0
4	VIVK - Vivakor, Inc.	——
5	Inno Holdings Inc.INHD	0%new
6	Silo Pharma Inc.SILO	0%new
7	Onfolio Holdings, Inc.ONFO	0%-0.05
8	SU Group Holdings LimitedSUGP	0%+0
9	MSPR - MSP Recovery, Inc.	——
10	Linkers Industries LimitedLNKS	0%0

Clearmind Medicine Inc. Common Shares

Healthcare
Biotechnology

Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions. The company’s current work centers on researching and advancing treatments for alcohol use disorder and related behavioral health indications, using proprietary small-molecule drug candidates designed to target underlying neurobiological pathways. Clearmind Medicine also operates consumer-oriented and research-driven programs tied to its therapeutic platform, reflecting a broader approach that combines pharmaceutical development with adjacent product concepts. Based in Vancouver, Canada, with active research and development activities in Israel, Clearmind Medicine participates in the life sciences market through a specialized pipeline aimed at regulated medicine development. Its common shares are used by investors to gain exposure to the company’s ongoing biotech research, clinical programs, and intellectual property-driven business model.

Website

Location

1220 West 6th Avenue

Vancouver, BC, V6H 1A5

Canada

Social

What share of all stock conversation is about CMND?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Sep 17

Clearmind Medicine Inc. ($CMND) presented its non-hallucinogenic psychedelic research at a historic FDA hearing on the future of psychedelic-based medicine.
Lead candidate MEAI is being studied at Yale and Johns Hopkins for alcohol use disorder, a condition with a Phase 2a trial ongoing.
Clearmind Medicine's stock ($CMND) is experiencing increased volume, with some analysts predicting a potential price range of $1.50-2.

Generated by AI

Sentiment

Of the messages about CMND that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	88.66% -11.34	76.66% -9.51
Bearish	—	—	11.34% +11.34	23.34% +9.51

Bullish· Aug 31

The company's low float and high short interest (CTB) make it a prime target for a squeeze, which could lead to significant price increases.
The stock's current setup, with a coiling pattern, suggests it is preparing for a major pop, potentially exceeding $3 per share.
With a large number of warrants outstanding, the company's stock is expected to see significant buying pressure, making it a good opportunity for investors to make a profit.

Bearish· Sep 4

The company's stock price has been declining, with a 52-week low expected to be reached later in the day.
There is a high level of short selling in the stock, with many investors expecting it to collapse.
The company's stock has been unable to recover from a significant decline, with no interest from buyers and a low price point that may not be able to cross $2.

Generated by AI

Topics

Of the messages about CMND that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	95.83%	83.96%	38.56%
Technical Analysis	100%	4.17%	14.15%	25.18%
Controversies	0%	0%	1.89%	0.06%
Analysts	0%	0%	0%	21.39%
Earnings	0%	0%	0%	0.03%
Macro	0%	0%	0%	14.78%

Announcements· May 29

Clearmind Medicine Inc. ($CMND) filed a Japanese patent application for MEAI, a non-hallucinogenic psychedelic compound for depression treatment.
The patent filing is part of Clearmind's expansion of its global intellectual property portfolio, which spans multiple jurisdictions with multiple granted patents and applications.
Clearmind Medicine's stock surged 95% after the patent filing, with the company also advancing its CMND-100 Phase I/II trial for alcohol use disorder at Johns Hopkins and Yale.

Technical Analysis· Apr 20

The 10M MACD for CMND has crossed, indicating strong buying pressure and a potential move.
The stock has halted after a strong push, suggesting an imbalance between buyers and sellers, with the reaction after the reopen being crucial.
CMND is breaking out on volume, with a tight float and consolidation finally breaking, and the price action speaking for itself.

Generated by AI

Community

Of the messages about CMND, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	74.58%	33.06%
Newcomers	0%	0%	25.42%	66.94%

Regulars· Sep 4

Clearmind Medicine has signed a definitive agreement to acquire a 51% stake in Charging Robotics, a wireless charging company for automated parking and robotaxis, for $2.5 million.
The acquisition is expected to add wireless charging technology to Clearmind Medicine's product portfolio, potentially expanding its reach in the automated parking and robotaxis markets.
Regular participants are divided on the implications of this acquisition, with some viewing it as a positive development and others warning of potential liquidity issues or a "pump and dump" scenario.

Newcomers· Sep 4

Clearmind Medicine Inc. has announced a $2.5M deal to acquire a 51% stake in an EV wireless charging firm, Charging Robotics, and also expects to close a $1.5M loan at 4%.
The acquisition and news release have caused a strong reaction on the market, with some users speculating about the potential impact on the company's stock price.
Some users are skeptical about the news and the potential for a short attack, with one user stating that there is no reason for trading view to put this news out there if it's not true.

Generated by AI

Clearmind Medicine Inc. Common Shares

Social

Sep 17

Bullish· Aug 31

Bearish· Sep 4

Announcements· May 29

Technical Analysis· Apr 20

Regulars· Sep 4

Newcomers· Sep 4

NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

Clearmind testifies at FDA hearing on psychedelic therapies

Clearmind enrolls first AUD patients in CMND-100 clinical trial

Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million

Clearmind Medicine Stock Slides Friday: What's Happening?

Also Discussed

Clearmind Medicine Inc. Common Shares

Company Information

Location

NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

Clearmind testifies at FDA hearing on psychedelic therapies

Clearmind enrolls first AUD patients in CMND-100 clinical trial

Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million

Clearmind Medicine Stock Slides Friday: What's Happening?

Also Discussed

Social

Sep 17

Bullish· Aug 31

Bearish· Sep 4

Announcements· May 29

Technical Analysis· Apr 20

Regulars· Sep 4

Newcomers· Sep 4